
Abbott received CE Mark approval for the AVEIR dual chamber (DR) leadless pacemaker system, the world's first to treat abnormal heart rhythms with beat-to-beat wireless communication. This innovation, featuring two small devices for right ventricle and atrium pacing, eliminates the need for cardiac leads, reducing complications and recovery time. AVEIR DR's synchronized pacing technology, based on Abbott's i2i communication, significantly enhances patient care. The system met primary safety and efficacy endpoints in clinical studies and gained US FDA approval in June 2023.
Like
Save
Share